Immunogenic cell death as interplay between physical anticancer modalities and immunotherapy.

Area of Science:

• Oncology
• Immunology
• Medical Physics

Background:

• Current cancer treatments face limitations including resistance, recurrence, and severe side effects from non-specific therapies like chemotherapy.
• Physical ablation techniques offer targeted treatment with reduced patient stress and faster recovery.
• Radiotherapy (RT) is established, but focused ultrasound (FUS) is emerging as a precise physical ablation method.

Purpose of the Study:

• To review how physical ablation therapies, specifically FUS, can leverage immunogenic cell death (ICD) to stimulate anticancer immunity.
• To explore the potential of these therapies to complement existing immunotherapies for improved cancer treatment outcomes.
• To highlight the shift from complete tumor ablation to milder applications that induce ICD without significant tissue damage.

Main Methods:

• Review of current literature on physical ablation techniques, focusing on focused ultrasound (FUS).
• Analysis of the mechanisms by which FUS induces immunogenic cell death (ICD).
• Exploration of the role of ICD in stimulating systemic anticancer immune responses and abscopal effects.

Main Results:

• Physical ablation therapies, particularly FUS, can induce immunogenic cell death (ICD), a process that alerts and activates the immune system against cancer.
• ICD triggered by FUS can lead to systemic immune responses, potentially enhancing the efficacy of other cancer treatments.
• Controlled application of FUS can achieve therapeutic benefits by inducing ICD while minimizing damage to surrounding healthy tissues.

Conclusions:

• Physical ablation therapies, especially FUS, represent a promising strategy for harnessing the immune system to fight cancer.
• The induction of ICD by FUS offers a novel approach to enhance anticancer immunity and improve patient outcomes.
• Combining FUS-induced ICD with immunotherapy holds significant potential for advancing cancer treatment paradigms.